Patient derived organoids (PDOs) are novel in vitro 3D cell models that preserve original tissue physiology and molecular pathology, thus representing a clinically-relevant alternative to traditional 2D cell lines and an effective tool to refine and reduce animal models. PDOs can be derived from adult patient biopsies or resected tissues containing native LGR5+ stem cell populations and cultured within an ECM-rich substrate using specialized organoid media such as L-WRN conditioned media. Adult tissue derived organoids are phenotypically and genetically stable in long term culture, presenting more mature phenotypes compared to iPSC-derived organoids. Importantly, PDOs have shown to be able to predict patient clinical responses to chemotherapeutics.
We are now offering a comprehensive biobank of highly characterized tissue-derived human gastrointestinal organoids from normal and diseased patients. The intestinal organoid biobank contains over 50 highly characterized intestinal organoids from both normal and diseased patients derived from multiple regions of the digestive systems including small intestine (duodenum, ileum), stomach, rectum and colon.
Cell Line Characteristics
- Sex: Male
- Age: 55 Years
- Organ: Colon
- Disease: Normal
Cell Line Origin
≥1500 viable organoids/vial
- Viability: ≥1500 viable organoids/vial
- Organoid Growth: Pass
- Cells are tested negative for infectious diseases by a Human Essential CLEAR panel by Charles River Animal Diagnostic Services.
- Mycoplasma Contamination: Negative
- STR Profile: Pass
Storage and Stability
Store in liquid nitrogen. The organoids can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
3dGRO™ organoids were derived utilizing HUB Organoid Technology
3dGRO is a trademark of Merck KGaA, Darmstadt, Germany